Recent Advances in Biology and Treatment of Multiple Myeloma
نویسندگان
چکیده
منابع مشابه
Myeloma bone disease: recent advances in biology, diagnosis, and treatment.
Bone disease is a hallmark of multiple myeloma (MM). Occurring in the majority of MM patients, it is associated with bone pain, fractures, and hypercalcemia and has major impacts on quality of life. Furthermore, bone resorption activity has been shown to be an independent risk factor for overall survival in patients with symptomatic MM. Myeloma is characterized by a unique form of bone disease ...
متن کاملAdvances in the biology and treatment of multiple myeloma.
Advances in the understanding of the cellular and molecular derangements involved in the initiation and progression of multiple myeloma are beginning to be translated into novel therapeutic approaches. The myeloma stem cell has been under intense scrutiny regarding its normal B-cell counterpart. Oncogenes, tumor-suppressor genes, and cell-survival genes have all been found to be dysregulated in...
متن کامل[The Cutting-edge of Medicine; Recent advances in biology and treatment of multiple myeloma].
A multistep process of ordered genetic changes leads to the development of overt multiple myeloma. This includes changes in the bone marrow microenvironment supporting tumor growth and failure of the immune system to control the disease. Primary translocations are mediated mainly by errors in immunoglobulin (Ig) heavy-chain switch recombination, but are sometimes also caused by errors in somati...
متن کاملRecent Advances of Thalidomide in the Treatment of Multiple Myeloma
1 st International Lymphoma Leukemia Myeloma (LLM) Congress Multiple Myeloma (MM) is a chemoresistant malignancy and for decades, the only active drugs were alkylating agents and high-dose corticosteroids. The introduction of novel agents (Thalidomide, Bortezomib and Lenalidomide) is changing the management of MM patients both for frontline therapy and at relapse. These agents have a different ...
متن کاملRecent advances in the treatment of multiple myeloma.
Multiple myeloma, a clonal B-cell malignancy, accounts for 10% of all hematologic cancers. In patients with multiple myeloma, median survival is approximately 30 to 36 months with conventional therapy, but high-dose chemotherapy resulted in better outcomes in a mature randomized trial. Pamidronate and other bisphosponates, used as supportive therapy, effectively reduce the incidence of skeletal...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nihon Naika Gakkai Zasshi
سال: 2015
ISSN: 0021-5384,1883-2083
DOI: 10.2169/naika.104.305